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ABSTRACT
CDC20 is a critical molecule in the Spindle Assembly
Checkpoint (SAC). It activates the Anaphase pro-
moting complex and helps a dividing cell to proceed
towards Anaphase. CDC20 is overexpressed in
many tumor cells which cause chromosomal
instability. There have been limited reports on the
mechanism of SAC’s response to genotoxic stress.
We show that ectopically expressed p53 or DNA
damage induced endogenous p53 can downregulate
Cdc20 transcriptionally. We have identified a con-
sensus p53-binding site on the Cdc20 promoter
and have shown that it is being used by p53
to bind the promoter and bring about chromatin
remodeling thereby repressing Cdc20. Additionally,
p53 also downregulates Cdc20 promoter through
CDE/CHR element, but in a p21 independent
manner. This CDE/CHR element-mediated down-
regulation occurs only under p53 overexpressed
condition but not in the context of DNA damage.
The present results suggest that the two CCAAT
elements in the Cdc20 promoter are not used by
p53 to downregulate its activity, as reported earlier.
INTRODUCTION
The spindle assembly checkpoint (SAC) is the surveillance
system that maintains genomic stability by ensuring the
proper segregation of chromosomes during mitosis. SAC
remains activated and cells are arrested at metaphase until
all sister chromatids bind to the bipolar spindle. Mad2
and BubR1, key components of the Mitotic Checkpoint
Complex (MCC), bind and inhibit CDC20 activity, which
is necessary for the activation of anaphase promoting
complex (APC) (1,2). Thus, the cell cycle is arrested at
metaphase when the checkpoint detects any defects
in microtubule–kinetochore attachment or in the tension
of the spindles (3–5). Only after ensuring proper attach-
ment of the sister chromatids, the MCC complex detach
from CDC20 and free CDC20 can activate APC. Active
APCCDC20 is the ubiquitin ligase that degrades Securin
thereby releasing the nuclear protease Separase (2). Free
and active Separase cleaves Cohesin, which till now held
the two sister chromatids together (6). The chromatids
then migrate to the two poles of the dividing cell thereby
ensuing Anaphase.
The tumor suppressor gene p53 is activated at the
nucleus by a variety of genotoxic stresses such as DNA
damage, hypoxia, oxidative stress and heat shock (7–9).
Activated p53 protein directly and indirectly regulates
transcription of many genes that are involved in cell
cycle, apoptosis and cellular senescence, and subsequently
inhibits malignant transformation and tumor progression.
p53 has been implicated in various cell cycle checkpoints
like the G1/S and G2/M (10,11). Few studies in fibroblasts
and yeast have implicated p53 to function as a checkpoint
at mitosis. When the mitotic spindle was disrupted in
wild-type fibroblasts by drug treatment, it was observed
that the cells arrested division, whereas in p53-deficient
cells there was failure to arrest, instead a new round
of cell division occurred resulting in polyploidy (12).
This phenotype was similar to that observed in yeast
strains that have inactivated SAC (13,14). Recently, p53
has also been reported to have role in the transcription of
the SAC gene Mad1L1 (6). It has been established
that p53 directly binds to the Mad1L1 promoter and
represses its transcription, but no p53 consensus site was
found. There have been recent reports of several genes
which are being targeted for repression by p53 like
DNA topoisomerase II, cyclin B, Cdc2, Mmp-1 and -13,
presenilin-1, myc, Map-4 etc, although, the actual mecha-
nism of this repression remains largely unexplained
(15–17). Transcriptional activation requires p53 to bind
a consensus sequence consisting of two copies of the
canonical site 50RRRC (A/T) (T/A) GYYY 30 separated
by 0–13 bp (6,18,19). But, the repression mechanism by
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p53 is much obscure. In some cases DNA binding is
required like -fetoprotein and Cdc2 (17,20). On the
other hand, p53 can also repress indirectly by interfering
with transcriptional factors which usually transactivate
the genes (21).
There have been reports of CDC20 overexpression
leading to aneuploidy and other chromosomal abnormal-
ities (22,23). Also, CDC20 has been shown to be over-
expressed in several cancer tissues (22,23). It has also
been suggested that apart from MCC-mediated sequestra-
tion, spindle checkpoint also reduces CDC20 level below
a certain threshold to ensure complete inhibition of APC
before anaphase (22). In the present study we observed
that the level of CDC20 decreased upon DNA damage
with the subsequent increase of p53 within the cell. We
show that wild-type p53 transcriptionally represses Cdc20
in several human cancer cell lines. Moreover, our studies
reveal that this repression is brought about by direct
binding of p53 to a bona fide p53 consensus binding
site in the promoter of Cdc20 resulting in chromatin
remodeling.
MATERIALS AND METHODS
Plasmids
Cdc20 promoter containing 999-bp upstream of the tran-
scription start site was amplified from human genomic
DNA with the primers 50TCTGAGCACATTCATACA
ATTCACTC30 (forward) and 50AACACGCCTGGCTT
ACGCCTCT30 (reverse). The amplified fragment was
cloned into the linearized pTZ57R/T (Fermentas,
Lithuania) utilizing T/A cloning method. The fragment
was then subcloned into the mammalian expression
vector pGL3 basic from Promega, (Madison, WI, USA)
using the restriction enzymes KpnI and XhoI (New
England Biolabs, Beverly, MA). The site directed muta-
tions of the NFY, CDE and p53-binding sites on the 1kb
Cdc20 promoter were created using the Site Directed
Mutagenesis Kit from Stratagene (La Jolla, CA, USA).
The primer sets used for the purpose is listed in
Supplementary Table 1. The wild-type p53 expression
plasmid pCMVp53 was a kind gift of Prof Bert
Vogelstein (Johns Hopkins University, Baltimore, USA).
The hTERT.Luc expression plasmid was a kind gift of Dr
Riccardo Dalla-Favera (Columbia University, NY, USA).
All the clones were checked by sequencing using the
ABI Big-Dye Terminator Kit (Applied Biosystems,
Foster City, CA, USA) and the 3130xl Genetic Analyser
(Applied Biosystems Foster City, CA, USA).
Cell lines, transfection and drug treatment
Human cell line HCT116 and MCF7 were purchased from
American Type Culture Collection (Manassas, VA, USA).
HCT116 (p53/ and p21/) cells were kind gifts of Dr
S. Das (Massachusetts General Hospital and Harvard
Medical School, Charlestown, MA). HepG2 cells were
gifted by Dr S. Adhya (Indian Institute of Chemical Biol-
ogy, India). All the cells were grown in DMEM
(Dulbecco’s Modified Eagle’s Medium; Invitrogen,
Carlsbad, CA, USA) supplemented with 10% (v/v) fetal
calf serum. Transient transfections were done with various
expression plasmids in different cell lines using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to manufacturer’s protocol and cells were har-
vested after 48 h. For induction of endogenous p53 pro-
tein, cells were treated with 1 mg/ml and 10 mg/ml of
5-fluoro uracil (5FU) and 10 mM, 25 mM and 50 mM
of Etoposide (Sigma, St Louis, USA). For release of
Histone Deacetylase-mediated gene repression the cells
were treated with 100 ng/ml and 250 ng/ml doses of
Trichostatin A (Calbiochem, San Diego, CA, USA)
respectively. The proteasomal inhibitor MG115 (Sigma,
St Louis, USA) was administered at a final concentration
of 25 mM and cells were incubated for 5 h.
RT–PCR
Total RNA from cell lines was isolated using TRIZOL
(Invitrogen, Carlsbad, USA) following manufacturer’s
protocol. Five micrograms of total RNA was treated
with DNAse in a total of 10 ml reaction volume. Two
microliters of this mixture was used for cDNA prepara-
tion using random hexamer and MMLV-RT from
Promega (Madison, WI, USA). The cDNA was then
PCR amplified using specific primers indicated in the
Supplementary Table 1.
Western blot
Western blots were done as described in (22). The primary
antibodies used were anti-p53 antibody in a dilution of
1:1000 from US Biologicals (Swampscott, MA, USA),
anti-CDC20 antibody in a dilution of 1:200 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-p21 antibody
in a dilution of 1:200 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and anti-b actin antibody at a dilution of
1:2000 (Sigma, St Louis, USA).
Chromatin immunoprecipitation (ChIP)
ChIP assay was done using the Quick ChIP kit from
Imgenex Corporation (San Diego, CA, USA) according
to manufacturer’s protocol. PCR amplification of precipi-
tated chromatin was done using primers indicated in the
Supplementary Table 1. Ten micrograms each of a-p53
antibody, a-HDAC1 antibody, a-mSin3A antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
anti-H3K9(Me)3 antibody (Abcam, Cambridge, MA,
USA) were used for the immunoprecipitation
Luciferase assay
After transfection and/or treatment, the cells were washed
with phosphate-buffered saline (PBS). The cells were then
lysed in the luciferase cell culture lysis buffer provided
with the Luciferase Assay Kit (Promega, Madison,
USA). After a brief vortex, whole cell lysates were centri-
fuged in the cold at 12 000 rpm for 2min. Supernatant
was collected in a fresh tube and 20–30 ml of that was
added to luciferase assay substrate (60–80 ml). Lumines-
cence was measured as relative light units (RLU), twice
for each lysate, taking the reading of luciferase assay
substrate alone and then with lysate in, GLOMAX
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(Promega, Madison, WI, USA). The value obtained for
luciferase assay substrate without lysate was subtracted
from respective RLU value for each lysate with luciferase
assay reagent. The total protein concentration in each
lysate was determined with a protein assay kit (Sigma,
St Louis, USA) and subsequently used to normalize the
luciferase activity. Each assay was done in duplicate and
repeated for three times. Fold repression values were
represented as mean of the three experiments.
Electrophoretic mobility shift assay
The double-stranded oligonucleotides were prepared by
annealing sense and anti-sense oligonucleotides (Supple-
mentary Table 1) and labeled with [g32P] ATP and T4
polynucleotide kinase (Promega, Madison, WI, USA).
Nuclear extracts from HepG2 cells treated with 5FU
were used in the assay. For competition assay a 100-fold
molar excess of unlabeled DNA oligonucleotides were
added before incubation. After incubation, each sample
was electrophoresed in a native 7% polyacrylamide gel.
The gels were dried and exposed for autoradiography at
208C. For supershift assay 5 mg of anti-p53 antibody was
used (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
RESULT
Downregulation of CDC20 by wild-type p53
We examined the effect of p53 on Cdc20 mRNA and pro-
tein expression. Negative regulation of Cdc20 by ectopic
expression of p53 was noticed both at the mRNA and
protein levels in HCT116 p53/ cells (Figure 1A and
B). Next, we investigated whether endogenous p53 could
suppress Cdc20 expression. HepG2 cells were treated with
two different DNA damaging drugs, 5-FU and etoposide.
As shown in Figure 1C and D, accumulation of p53 and
subsequent suppression of CDC20 was observed with
1 mg/ml concentration of 5FU and 10 mM of etoposide.
To eliminate the possibility of the decrease in CDC20
level due to protein degradation, we treated HepG2 cells
with the proteasomal inhibitor MG115 along with 5FU.
As seen in Figure 1E, treatment with MG115 failed to
restore CDC20 protein level, whereas degradation of
endogenous p53 in the absence of 5FU was stopped by
MG115 (Figure 1F).
p53 downregulates CDC20 at the transcription level
After eliminating the possibility of p53-mediated pro-
teasomal degradation of CDC20, we asked whether
the repression occurred at the level of transcription.
Towards that end, we amplified 1 kb [nt # 43254437 to
nt # 43255456, Accession Number 113772 TRED (http://
rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home)]
region of human Cdc20 including the transcription start
site by PCR and cloned it into a luciferase assay vector
pGL3 basic. Because the pGL3 basic vector did not
contain any promoter or enhancer sequences, detectable
luciferase activity indicated that 1-kb sequence possessed
the Cdc20 promoter activity (Figure 2A and B). To con-
firm the effect of p53 on Cdc20 promoter we cotransfected
the p53 null cell line, HCT116 p53/ with the reporter
construct and increasing amounts of wild-type p53 expres-
sion vector pCMVp53. As observed in Figure 2B, with
250 ng concentration of pCMVp53 vector there is almost
2-fold decrease in promoter activity, indicating that the
p53 induced suppressive effect on Cdc20 is a transcrip-
tional phenomenon. The downregulation of Cdc20
promoter driven luciferase activity was also examined
by inducing endogenous p53 in HepG2 cells treated with
5FU and Etoposide (Figure 2C and D). In both the cases
a dose dependent decrease (2–3.5-fold) in luciferase activ-
ity was observed. These results indicated that p53 tran-
scriptionally repressed the expression of CDC20 in a
dose-dependent manner, and this effect was physiological
and not cell type specific.
CDC20 is downregulated by direct binding of
wild-type p53 to its promoter
Having observed that the downregulation of Cdc20 by
wild-type p53 is at the transcription level, we examined
whether p53 is physically present in the transcription com-
plex on the Cdc20 promoter. We first scanned the
upstream 1kb region of the Cdc20 promoter which we
had cloned in the luciferase reporter assay system for the
presence of a consensus p53-binding region. We could
identify the presence of a putative consensus p53-binding
site 689 bases upstream of the transcriptional start
site comprising of two copies of the sequence, 50-RRRC
(A/T) (T/A) GYYY-30 separated by 17 bp (Figure 3A).
Next, we used synthetically prepared oligos containing
the sequence corresponding to the putative p53-binding
site and performed an EMSA using nuclear extract from
HepG2 cells treated with 5FU. We found strong binding
of the radioisotope-labeled oligo with the nuclear extract
and this band disappeared when the nuclear extract was
previously incubated with excess of unlabeled oligo thus
proving the specificity of the binding (Figure 3B).
Moreover, when a supershift assay was done using anti-
body against p53 protein there was a prominent shift in
the band, thus indicating the presence of p53 in the com-
plex, binding the sequence (Figure 3B). Furthermore,
we wanted to check for the specificity and strength of
binding of p53 with the sequence. Towards that, we incu-
bated the nuclear extract from 5FU-treated HepG2 cells
with the well-characterized p21 promoter sequence that
binds p53 (24). The complex thus formed was chased
by excess of non-radiolabeled probes of both p21 and
Cdc20 promoter sequences. In parallel, the complex
formed between 5FU treated HepG2 nuclear extract and
the Cdc20 promoter sequence could also be chased by
excess of cold p21 promoter oligo. In both the cases the
chase were of comparable efficiency indicating that the
Cdc20 promoter sequence binds p53 with appreciable
efficiency and the strength of binding is comparable to
that of p21 promoter (Figure 3B). This finding was further
validated by ChIP. In MCF7 cells, treated with 5FU,
chromatin precipitation was done using anti-p53 antibody
and the precipitated DNA was PCR amplified using
primers specific for a region of the Cdc20 promoter
(Figure 3C). Amplification was observed in MCF7 cells
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treated with 5FU indicating that p53 was present
physically in the transcription complex on the Cdc20 pro-
moter. Also, HCT116 p53/ cells were transfected with
pCMVp53 construct followed by ChIP, and a positive
amplification was observed when anti-p53 antibody was
used for immunoprecipitation (Figure 3D).
There have been several reports of p53 repressing
genes via the p21, NFY and E2F pathways (7,25). One
such report also implicates the role of NFY and E2F in
the repression of Cdc20 by p53 (7). Therefore, we wanted
to study whether p53 independently could use this newly
identified binding site on Cdc20 promoter to bring
about the repression. We constructed several Cdc20
promoter mutants where NFY, E2F (CDE/CHR) and
p53-binding sites were mutated singly or in combinations
(Figure 4A). These constructs were transfected in
HCT116p53 / cells in presence or absence of p53 expres-
sion vector pCMVp53. It was seen that even with both the
NFY and CDE sites mutated (pTB3), ectopic expression
of p53 could bring about the repression of CDC20, albeit
to a lesser extent (Figure 4B). Notably, when the
p53-binding site was mutated in conjunction with the
NFY and CDE sites (pTB7) no effect of p53 overexpres-
sion was detected on the Cdc20 promoter. These results
indicated quite conclusively that p53 was using the direct
binding site, independent of NFY and CDE. It was also
seen that when HCT116 p53/ cells were cotransfected
with reporter constructs having mutations for both the
NFY and p53 sites (pTB4) or only the p53 site (pTB5)
along with pCMVp53, there was appreciable downregula-
tion in promoter activity. These results suggest that p53
can also inhibit Cdc20 promoter through an indirect
Figure 1. (A) HCT116 p53/ cells were transiently transfected with 0, 1, 2, 3 and 4mg of pCMVp53 expression plasmids. RT–PCR was done for p53
and Cdc20 and -actin taken as internal control. It was seen that with increase in the level of p53 mRNA, the Cdc20 mRNA decreases. (B) HCT116
p53/ cells transiently transfected with 0, 250 and 500 ng of pCMVp53 vector and the total protein isolated followed by western blot analysis
with anti-p53, anti-CDC20 and anti-b-actin antibodies. It was observed that, with increase in p53 protein, the level of CDC20 protein decreased.
(C) HepG2 cells were treated with 0, 1 and 10 mg/ml 5-FU for 48 h followed by western blot analysis. With increasing doses of the DNA damaging
drug within the cell, endogenous p53 protein level increased with subsequent decrease in CDC20 protein level. (D) HepG2 cells were treated with 0,
10, 25 and 50 mM concentrations of Etoposide for 24 h followed by western blot analysis. It was observed that, with increasing drug, the endogenous
p53 protein level increased with subsequent decrease in CDC20 protein level. (E) HepG2 cells expressing higher levels of p53 due to 5-FU treatment
showed no increase in CDC20 protein level when treated with the proteasomal inhibitor MG115 indicating that the decrease in CDC20 protein with
increasing p53 protein level was not due to proteasomal-mediated protein degradation. (F) Western blot analysis of HepG2 cells treated with MG115
in the absence of 5-FU showed inhibition of degradation of endogenous p53.
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pathway, as suggested by others (Figure 4A). Another
notable observation here is that the fold repression of
pTB2 (with both NFY RE sites mutated) is comparable
to that of the wild-type promoter construct pTB1 while
in pTB6 having the p53 site and CDE mutated and only
NFY site functional do not get repressed by p53. In all the
cases NFY RE mutation does not have any additional
effect on the p53-mediated repression, indicating that
NFY does not have a role in p53-mediated CDC20 repres-
sion, contrary to what have been reported before (25).
These results were further validated by studying the
effect of p53 on Cdc20 promoter in a p21 null cell line
HCT116 p21/. Here also, we found that p53 could
considerably repress the luciferase expression driven by
wild-type (pTB1) or CDE and NFY mutated (pTB3)
Cdc20 promoter (Figure 4C), thus reinforcing the fact
that there is a mechanism of p53-mediated repression
of CDC20 independent of p21. Interestingly here, the
NFY and p53 double mutant construct (pTB4) showed
downregulation in promoter activity when p53 was over-
expressed (Figure 4C). These results suggest that p53 can
inhibit Cdc20 promoter activity through CDE-binding
site independent of p21 pathway.
We finally measured the mutant promoter activities
by inducing endogenous p53 in the HCT116 p21/ cells
to mimic a more physiological condition (Figure 4D). As
expected, wt Cdc20 promoter luciferase construct (pTB1)
exhibited considerable downregulation upon activation
of endogenous p53 both by 5FU and etoposide. However,
drug induced p53 failed to downregulate the Cdc20 pro-
moter which was mutated at the p53-binding site (pTB5)
or both the NFY and p53-binding sites (pTB4) whereas,
constructs with NFY (pTB2) and NFY-CDE mutations
(pTB3) showed significant repression. Here what is
Figure 2. (A) 1 kb DNA sequence upstream of the start site of Cdc20 transcription was cloned into the pGL3 basic vector such that it transcribes the
luciferase gene. (B) HCT116 p53/ cells were transiently co-transfected with pTB1 vector along with 0, 50,100, 250, 500 and 1000 ng of pCMVp53
vector followed by luciferase assay after 48 h. With increasing p53 expression the luciferase expression driven by the Cdc20 promoter reduces.
(C) HepG2 cells transfected with pTB1 were treated with 0, 1 and 10 mg/ml of 5FU followed by luciferase assay after 48 h. The luciferase activity
decreased subsequently with increasing drug dose. (D) HepG2 cells transfected with pTB1 were treated with 0, 10, 25 and 50 mM of Etoposide
followed by luciferase assay after 48 h. The Cdc20 promoter driven luciferase activity decreased with increasing drug dose.
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notable is that all the constructs having the wild-type
p53-binding site (pTB1, pTB2 and pTB3), responded to
the drug-mediated p53 induction whereas in those clones
where the p53 site is mutated irrespective of the CDE site
being intact (pTB4, pTB5) there is no repression. Taken
together, these results suggest that physiological levels of
p53 inhibits Cdc20 promoter via the putative p53-binding
site whereas inhibition of Cdc20 promoter through indi-
rect pathway using the CDE site requires much higher
levels of p53 expression.
p53 downregulates CDC20 expression through
chromatin remodeling
After establishing that p53 binds directly to the Cdc20
promoter and represses its activity, we wanted to investi-
gate whether this binding induces chromatin remodeling
thereby causing the downregulation. We first, ectopically
expressed p53 in HCT116 p53/ cells and treated them
with increasing doses of the HDAC inhibitor Trichostatin
A (TSA). The luciferase activity driven by the Cdc20
Figure 3. (A) Cis elements on the Cdc20 promoter and the nucleotide sequence of the identified p53 direct binding site. (B) Electrophoretic mobility
shift assay done with the oligonucleotide sequence corresponding to the p53-binding site and nuclear extract from HepG2 cells treated with 5FU. The
first three lanes of the left panel show binding of the oligonucleotide and 1, 3 and 5 mg of the nuclear extract, the fourth lane shows the supershift
with anti-p53 antibody and the last lane is the chase with unlabeled probe (100 molar excess). In the right panel, the first three lanes correspond to
the binding of p53 from 5FU treated HepG2 nuclear extracts with Cdc20 promoter oligo and chase with 100 molar concentration of the non-
radiolabeled Cdc20 promoter oligo and p21 promoter oligo respectively. The next three lanes correspond to the binding of p53 from 5FU-treated
HepG2 nuclear extract with the well characterized p21 promoter oligo and chase with 100 molar concentration of non-radiolabeled p21 promoter
oligo and Cdc20 promoter oligo respectively. (C) ChIP in MCF7 cells treated with 5FU. Anti-p53 antibody was used to precipitate the chromatin–
protein complex and Cdc20 promoter-specific primers were used to amplify the precipitated DNA. (D) ChIP in HCT116 p53/ cells transfected with
1 mg of pCMVp53 vector. Anti-p53 antibody was used for immunoprecipitation and Cdc20 promoter-specific primers were used for amplification of
the precipitated DNA. A fraction of the input was loaded.
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promoter recovered as higher doses of TSA were adminis-
tered, indicating a role of HDACs in the p53-mediated
repression (Figure 5A). To eliminate the possibility of arbi-
trary release in repression by Trichostatin A we performed
an identical experiment using the human telomerase
reverse-transcriptase (hTERT) promoter, which is tran-
scriptionally downregulated by p53 in a HDAC indepen-
dent fashion (26,27). TSA could not release the repression
on hTERT promoter brought about by p53 (Figure 5B),
establishing the specificity of the drug action. We next
performed ChIP in HepG2 cells treated with 5FU where
immunoprecipitation was done using anti-p53 antibody,
anti-HDAC1 antibody and the antibody against
co-repressor mSin3A (Figure 5C). PCR amplification was
observed in all the three cases indicating the chromatin
remodelers HDAC1 and mSin3A to be present in the
transcription complex of Cdc20. To establish that the
recruitment of HDAC1 and mSin3A to the Cdc20 pro-
moter occurs only in the presence of p53, we treated
HCT116 p53/ cells with 5FU and then performed
ChIP using p53, HDAC1 and mSin3A antibodies, but no
amplification was observed (Figure 5D) indicating that
the chromatin remodelers did not bind to the Cdc20 pro-
moter in the absence of p53. Furthermore, to verify
whether this event was specific to the DNA damage con-
text we performed ChIP with HCT116 cells, which were
treated with or without 5FU. Immunoprecipitation was
done using antibodies specific for p53 and HDAC1.
Interestingly, we found that only in those cells which
were treated with the DNA damaging drug and having
higher levels of p53 protein and corresponding lower
levels of CDC20 (Figure 5G), gave a positive PCR
amplification for the Cdc20 promoter when immunopreci-
pitated with the two antibodies (Figure 5E). Also Histone3
lysine 9 tri-methyl-specific antibody could precipitate
the Cdc20 promoter in 5FU treated HCT116 cells com-
pared to the untreated one (Figure 5F). All these
results taken together indicate that DNA damage within
a cell induces p53 which is recruited to the Cdc20 pro-
moter and which in turn brings about transcriptional
downregulation by histone deacetylation and histone
methylation.
Figure 4. (A) The NFY and E2F response elements and putative p53-binding site on the Cdc20 promoter have been mutated by site directed
mutagenesis. The crossed boxes refer to the mutated responsive elements. (B) Luciferase assays done in HCT116 p53/ cell with different mutants
(as indicated) in presence or absence of wild-type p53 overexpression. (C) Luciferase assay performed in HCT116 p21/ cells with the different
mutants along with ectopic expression of wild-type p53. (D) Luciferase assay performed in HCT116 p21/ cells with the different mutants in
presence of the DNA damaging drugs 5FU and Etoposide.
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Figure 5. (A) HCT116 p53/ cells cotransfected with pTB1 and pCMVp53 expression vectors were treated with increasing doses of the HDAC
inhibitor Trichostatin A (TSA) and luciferase assay was performed after 48 h. Luciferase acivity is expressed as Relative Light Unit (RLU)
per microgram of total protein. (B) HCT116 p53/ cells cotransfected with hTERT prom-luc and pCMVp53 expression vectors were treated
with increasing doses of TSA and luciferase assay was performed after 48 h. Luciferase activity is expressed as RLU per microgram of total protein.
(C) ChIP assay was done in 5-FU treated HepG2 cells with anti-p53, anti-HDAC1 and anti-mSin3A antibodies and the precipitated chromatin
amplified using primers specific for the Cdc20 promoter. (D) ChIP assay was done in 5FU treated HCT116 p53/with anti-p53, anti-HDAC1, anti-
mSin3A and anti-RNA pol II antibodies and the precipitated DNA was amplified using primers specific for the Cdc20 promoter. (E) ChIP done in
HCT116 cells treated or untreated with 5-FU. Amplification with the Cdc20 promoter specific primer was observed in chromatin precipitated with
anti-p53 and anti-HDAC1 antibodies only in the treated cells but not in the untreated cells. (F) ChIP done in HCT116 cells treated with or without
5-FU. Immunoprecipitation was done using antibody against Histone3 lysine 9 tri-methylation and the precipitated DNA amplified using CDC20
promoter-specific primers. (G) Western blot analysis of HCT 116 cells treated with or without 5FU using anti-p53, anti-CDC20 and anti- b-actin
antibodies showed an increase in endogenous p53 level with consequent decrease in CDC20 level upon drug treatment.
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DISCUSSION
Extensive studies have established p53 to be a key gene,
which is activated upon cellular stress or DNA damage
(8,21,25,28). Activated p53 has been found to transacti-
vate a number of genes (10) but there has been increasing
evidence of several genes which are also repressed by p53
(6,8,9,29). There is report of 129 genes from both human
and viral genomes which contain the p53 consensus
response element (RE) (30). About 160 REs have been
reported of the 129 identified p53 responsive genes (several
genes have multiple REs). A number of genes like
stathmin, AbcB1, Birc5 (survivin), Hsp90, etc. are
repressed by p53 via their responsive elements, upon
several stress signals (28,29). The current consensus is
that there are four criteria that are to be fulfilled for a
particular sequence to be designated as a bona fide p53
direct binding responsive element and the gene to be a
p53 responsive target (30). First, is the presence of a p53
RE in the DNA close to the gene or within the gene.
Second, is to demonstrate that the particular gene
is upregulated or downregulated at the RNA and
protein level by wild-type p53 protein. The third
line of evidence is to clone the RE upstream of any
reporter gene like luciferase and show that p53 induc-
tion can regulate this test gene in the same fashion as
the gene of interest. Finally, it has to be established by
ChIP using specific p53 antibody, that p53 physically
interacts with the RE and binds to the chromatin. In
some cases a gel-shift assay is also done additionally to
demonstrate the binding in vitro. Here, in this study we
have fulfilled all the above criteria and have established
the SAC gene Cdc20 to be downregulated by p53 upon
DNA damage where activated p53 directly binds to the
RE located 689-bp upstream of the transcription start
site (TSS).
The putative p53-binding site on theCdc20 promoter has
two half sites conforming to the 50-RRRCWWGYY-30
(where R is a purine, Y is a pyramidine, W is either A or
T, G is guanine and C cytosine) rule. These half sites are
separated by an 17-bp spacer. Each quadrate of the half
sites is arranged in the head to head orientation. All these
are in conformation with the requirements of a sequence
to be a p53 RE (30). However, careful analysis of the
p53 RE of Cdc20 promoter revealed few deviations from
the consensus motif. It has been noted that the central
CWWG sequence of the half site is highly conserved
in experimentally verified p53 REs (18,19,30). The first C
is replaced by G in the left half site of the Cdc20 p53 RE
(Figure 3A). Similarly, instead ofWW this p53RE contains
CW andWG in the left and right half-site respectively. It is
known that p53 RE is highly degenerate and deviations
from the consensus sequence have been noted in many
p53 responsive genes, including both which are activated
or repressed by p53. Another important component of
the p53 RE is the length of the spacer between the two
half-sites. Recent analysis suggests that on an average,
p53-repressor biding sites have significantly longer spacer
length than that of p53 activator sites (30). The observed
17-bp spacer length between the two half-site of the Cdc20
p53 RE is in conformity with these findings.
p53 downregulates genes both by direct and indirect
mechanisms (21). At present, three generally accepted
methods of direct p53-mediated repression are known:
first, binding site overlap (steric interference) (20);
second, p53 squelching of transcriptional activators (17);
and third, p53-mediated recruitment of histone deacety-
lases (HDACs) (30,31). There are two generally accepted
modes of indirect p53-mediated repression. The first is
brought about by activation of CDKN1A (p21WAF),
which in turn inhibits cyclinD–CDK4 complex through
direct binding (25,30). The consequence of this inhibition
is the absence of hyperphosphorylation of the Rb protein.
Unphosphorylated Rb represses the function of the
E2F family of transcription factors. Also, on the other
hand inhibited cyclinD–CDK4 complex cannot phosphor-
ylate transcription factor NFY to perform its necessary
functions (25). In the second mode of indirect repression,
p53 binds to another transcription factor and represses
the target gene without any p53-specific RE (6). There
have been reports of the Cdc20 gene being repressed by
the indirect mechanism through CDKN1A activation
(7,25). The reports have identified NFY and E2F respon-
sive elements on the promoter region of Cdc20, which
transactivate the gene under normal condition. Upon
p53 induction, p21 level is increased within the cell,
hence E2F and NFY can no longer activate Cdc20
resulting in a decrease in CDC20 level. But, in our study
we have given evidence of p53 direct binding to the Cdc20
promoter in the context of DNA damage. We have
performed ChIP assay to show that after DNA damage
p53 binds to the Cdc20 promoter, which in turn recruits
the co-repressor mSin3A and the histone deacetylase
HDAC1. Also, ChIP studies have shown histone methyla-
tion of the Cdc20 promoter chromatin to occur in presence
of p53. These are in agreement with the already estab-
lished mechanism of p53-mediated direct repression
of genes (30). We have also generated site-directed
mutations of the NFY and E2F-binding sites of the
Cdc20 promoter and have done reporter assays with
these mutants to show that even in absence of the indirect
repression mechanism, p53 can bring about further repres-
sion of the Cdc20 gene by direct binding. This has
been further proved by performing the studies in a p21
null cell line. Thus, the existence of both the direct and
the indirect pathway for p53-mediated downregulation
of Cdc20 gene is operating in DNA damaged cells. A
few additional informations on the indirect mechanism
of repression have emerged from this study. First, p53
represses Cdc20 promoter via CDE/CHR element in
p21 independent manner. The exact mechanism of CDE/
CHR-mediated Cdc20 promoter repression remains
unclear. p21 independent CDE/CHR element-mediated
gene repression by p53 has also been reported for another
cell cycle checkpoint protein Cdc25C (21). Second, while
p53-mediated direct repression of Cdc20 promoter works
at more physiological condition, the CDE/CHR-mediated
indirect pathway operates at higher p53 levels (Figure 6).
Finally, we see that contrary to what has been reported till
now (25), the two CCAAT/NFY elements present on the
Cdc20 promoter do not contribute to the p53-mediated
transcriptional repression of the gene.
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Under cellular stress or DNA damage cell division
is halted to allow time to correct the damage or over-
come the stress by activating several cell-cycle checkpoints
(2). Indeed major cell cycle checkpoints such as G1/S,
G2/M and SAC are known to be regulated by activated
p53 in response to DNA damage or other cellular stress
(8,10,25). Although, the regulation of G1/S and G2/M
by activated p53 is known in great detail, the regulation
of SAC by p53 in response to DNA damage is poorly
understood. As a dividing cell proceeds from metaphase,
the activated CDC20 protein primes the APC to initiate
Anaphase. We find that the APC activator, CDC20
is downregulated by the tumor suppressor protein p53
in response to various DNA damages. Previously, another
SAC gene Mad1L1 has also been reported to be down-
regulated by p53 under DNA damaged conditions (6).
Thus, it appears that tumor suppressor protein p53 uses
multiple genes as targets to control the SAC function. It
is conceivable that p53 would do so because the deregula-
tion of SAC is known to lead to chromosomal instability
(22). In human cancer cell lines and primary tumors
frequent mitotic abnormality due to overexpression/
underexpression of SAC genes have been reported
(32–34). Overexpression of CDC20 is known to initiate
premature anaphase leading to aneuploidy in tumor cells
(22). Furthermore, level of CDC20 is regulated in a cell
cycle dependent manner (1,2). Thus, a tight regulation of
CDC20 ensures proper checkpoint function which may be
controlled by p53 under cellular stress.
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